IpsenSTU:I7G +3.44%91 Price-to-Operating-Cash-Flow is 11.88 as of Jun. 24, 2026, which is 12% above its 10-year median of 10.64. GuruFocus rates STU:I7G with a GF Score™ of 91/100 and a GF Value™ of €133.06 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 701 Drug Manufacturers companies, Ipsen ranks better than 62.91% on this metric.
As of today (2026-06-24), Ipsen's share price is €162.20.
Ipsen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €13.66. Hence, Ipsen's Price-to-Operating-Cash-Flow Ratio for today is 11.88.
The historical rank and industry rank for Ipsen's Price-to-Operating-Cash-Flow or its related term are showing as below:
STU:I7G'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.34 Med: 10.64 Max: 32.58
Current: 11.91
During the past 13 years, Ipsen's highest Price-to-Operating-Cash-Flow Ratio was 32.58. The lowest was 5.34. And the median was 10.64.
STU:I7G's Price-to-Operating-Cash-Flow is ranked better than 62.91% of 701
companies
in the Drug Manufacturers industry
Industry Median: 16.12
vs STU:I7G: 11.91
Ipsen's Cash Flow from Operations per share for the
six
months ended in Dec. 2025 was €7.35.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €13.66.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Ipsen was 24.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 5.60% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 15.50% per year.
During the past 13 years, Ipsen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 36.40% per year. The lowest was -17.30% per year. And the median was 12.70% per year.
Ipsen Price-to-Operating-Cash-Flow Related Terms
Ipsen Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Ipsen's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:I7G vs ZTS, UTHR, VTRS: Price-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Ipsen's Price-to-Operating-Cash-Flow falls into.
Ipsen's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
162.20
/
13.655
=
11.88
Ipsen's Share Price of today is €162.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €13.66.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 11.88 mean?
Ipsen (STU:I7G) has a Price-to-Operating-Cash-Flow of 11.88 as of Jun. 24, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Ipsen and its competitors. This is 12% above median its historical median of 10.64. Over the past decade, Ipsen's Price-to-Operating-Cash-Flow has ranged from 5.34 to 32.58. According to the industry distribution chart, Ipsen ranks #260 out of 701 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is Ipsen's Price-to-Operating-Cash-Flow too high?
Ipsen's current Price-to-Operating-Cash-Flow of 11.88 is 12% above median its 10-year median of 10.64. Over the past 10 years, this metric has ranged from a low of 5.34 to a high of 32.58. The Drug Manufacturers industry median Price-to-Operating-Cash-Flow is 16.12. Ipsen's value of 11.88 is 26.3% below this industry median. Based on the distribution chart, Ipsen ranks #260 out of 701 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ipsen has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Price-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #260 out of 701 companies for Price-to-Operating-Cash-Flow. This puts Ipsen in the upper half of its industry. The industry median Price-to-Operating-Cash-Flow is 16.12. Ipsen's value of 11.88 is 26.3% below this benchmark. Historically, Ipsen's own Price-to-Operating-Cash-Flow has ranged from 5.34 to 32.58 over the past decade. While the company's 10-year median is 10.64 vs. the industry median of 16.12, Ipsen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Price-to-Operating-Cash-Flow among Drug Manufacturers companies is 16.12, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current Price-to-Operating-Cash-Flow of 11.88 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median Price-to-Operating-Cash-Flow is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current Price-to-Operating-Cash-Flow is 11.88, which is 12% above median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (STU:I7G) is currently considered Modestly Overvalued. The stock's GF Value™ is €133.06, compared to a current price of €162.20 — trading 21.9% above its estimated fair value. The current Price-to-Operating-Cash-Flow is 11.88, which is 12% above median its 10-year median of 10.64 and 26.3% below the Drug Manufacturers industry median of 16.12. Ipsen's overall GF Score™ is 91/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Ipsen (STU:I7G), the current Price-to-Operating-Cash-Flow is 11.88 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (STU:I7G) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of €162.20 is trading 21.9% above its estimated GF Value™ of €133.06.
GuruFocus considers Ipsen to be Modestly Overvalued.
Key valuation signals for STU:I7G:
Price-to-Operating-Cash-Flow: 11.88 (12% above median its 10-year median of 10.64)
GF Value™: €133.06 vs. price of €162.20 (21.9% above fair value)
Industry Position: 26.3% below the Drug Manufacturers median (#260 of 701)
No single metric tells the full story. See the STU:I7G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
91GF Score
Get the complete analysis for STU:I7G
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I7G has been successfully added to your 
